期刊文献+

整合素与肿瘤的靶向治疗 被引量:8

Integrins and Targeted Therapy of Cancer Therapy
下载PDF
导出
摘要 整合素是细胞表面重要的黏附分子,介导细胞与细胞外基质相互作用,在肿瘤的发生发展过程中起着重要的作用,近年来将整合素作为肿瘤治疗靶点取得了显著的进展。目前采用针对整合素不同亚基的克隆抗体,整合素抑制剂,靶向节调整合素基因表达,整合素介导的溶细胞作用以及肿瘤细胞的整合素疫苗等方法通过调节整合素的生物学作用,促进肿瘤细胞凋亡,阻断肿瘤细胞侵袭迁移,抑制肿瘤血管的生成,从而达到治疗肿瘤的目的。这些研究发现对开拓肿瘤治疗新方案有着重要的意义。 Integrins is the important adhesion molecule on the cell surface, which can mediate interactions between cells and the extracelluar matrix and play an important role in the genesis and devel opment of tumor. Great progresses have been achieved about integrins as the targeted therapy of cance therapy. Now many methods regulating biological effects of integrins, such as methods aiming at clon, antibody of different subunit of integrins, inhibitor of integrins, targeted regulated expression of integrins gene,cytolysis mediated by integrins, integrins vaccine of tumor ceils, and so on, can cure tumor b, promoting tumor cell apoptosis,blocking the invasion and metastasis of tumor,inhibitlng angiogenesis of tumor.These studies have great significance for exploring new therapy for tumor.
出处 《医学综述》 2008年第1期60-62,共3页 Medical Recapitulate
基金 国家自然基金资助项目(30271482)
关键词 肿瘤 整合素 靶向治疗 Neoplasm Integrin Targeted therapy
  • 相关文献

参考文献20

  • 1Dang D, Bamburg JR, Ramos DM. Alphavbeta 3 integrin and cofilin modulate K1735 melanoma cell invasion [ J ]. Exp Cell Res, 2006,312 (4) :468-477.
  • 2Oliver S,Bjarne K,Erika W, et al. Expression of alpha v beta 3 integrin in patients with high and low grade glioma[J]. Proc Am Assoc Cancer Res,2006,47(8) :53-54.
  • 3Park CC,Zhang H, Pallavicini M, et al. Betal integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo[J]. Cancer Res,2006,66(3) : 1526-1535.
  • 4Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-alpha5 betal integrln antibody as a novel anti-angiogenic agent [J] .J Exp Ther Oncol,2006,5(4) :273-286.
  • 5Trikha M,Zhou Z, Nemeth JA, et al. CNTO 95,a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic Activity in vivo [ J]. Int J Cancer, 2004,110 (3) : 326-335.
  • 6Mullamitha SA .Ton NC,-Parker GJ, et al.Phase Ⅰ evaluation of a fully human anti-alphav integrin monoclonal antibody ( CNTO 95 ) in patients with advanced solid tumors[ J ]. Clin Cancer Res, 2007, 13 ( 7 ) : 2128- 2135.
  • 7Patel SR, Jenkins J, Papadopalous N, et al. Pilot study of vitaxin an angiogenesis inhibitor-in patients with advanced leiomyosarcomas [ J ]. Cancer,2001,92(5): 1347-1348.
  • 8Tucker GC. Integrin molecular target in cancer therapy[J]. Curr Oncol Rep,2006,8(2) :96-103.
  • 9McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a moneclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion [ J ]. Clin Cancer Res, 2005,11 ( 21 ) : 7851-7860.
  • 10Eskens FA, Dumez H, Hoekstra R, et al. Phase Ⅰ and pharmacokinetie study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours[J]. Eur J Cancer, 2003,39(7) :917-926.

同被引文献181

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部